Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years

被引：0
|
作者：
Tawbi, Hussein A.
Hodi, F. Stephen
Lipson, Evan J.
Schadendorf, Dirk
Ascierto, Paolo Antonio
Matamala, Luis
Gutierrez, Erika Castillo
Rutkowski, Piotr
Gogas, Helen
Lao, Christopher D.
Menezes, Juliana
Dalle, Stephane
Arance, Ana Maria
Grob, Jean-Jacques
Ratto, Barbara
Rodriguez, Saima
Mazzei, Antonella
Dolfi, Sonia
Long, Georgina V.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Johns Hopkins Univ Sidney Kimmel Comprehens Canc, Baltimore, MD USA
[4] Univ Essen Gesamthsch, Essen, Germany
[5] German Canc Consortium, Partner Site, Essen, Germany
[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[7] Inst Oncol Fdn Arturo Lopez Perez, Santiago, Chile
[8] Inst Nacl Canc, Dept Oncol, Santiago, Chile
[9] FAICIC Clin Res, Veracruz, Veracruz, Mexico
[10] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[11] Natl & Kapodistrian Univ Athens, Athens, Greece
[12] Univ Michigan, Ann Arbor, MI 48109 USA
[13] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil
[14] Ctr Hosp Univ Lyon, Dermatol, Lyon, Rhone Alpes, France
[15] Hosp Clin Barcelona, Barcelona, Spain
[16] IDIBAPS, Barcelona, Spain
[17] Aix Marseille Univ, Hop Timone, Marseille, France
[18] Bristol Myers Squibb Co, Princeton, NJ USA
[19] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[20] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9524
引用
收藏
页数：1
相关论文
共 23 条
  • [1] Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047
    Hodi, F. S.
    Tawbi, H. A.
    Lipson, E. J.
    Schadendorf, D.
    Ascierto, P. A.
    Matamala, L. A.
    Salman, P.
    Gutierrez, E. C.
    Rutkowski, P.
    Gogas, H. J.
    Lao, C. D.
    Menezes, J.
    Dalle, S.
    Arance Fernandez, A. M.
    Grob, J. J.
    Keidel, S.
    Rodriguez, S.
    Wang, P.
    Dolfi, S.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S920 - S921
  • [2] Relatlimab (RELA) plus nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047
    Hodi, F. S.
    Tawbi, H. A.
    Lipson, E. J.
    Schadendorf, D.
    Ascierto, P. A.
    Matamala, L.
    Gutierrez, E. C.
    Rutkowski, P.
    Gogas, H. J.
    Lao, C. D.
    De Menezes, J. J.
    Dalle, S.
    Arance, A.
    Grob, J. J.
    Toms, L.
    Jonczak, K.
    Sobiesk, A. M.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S867 - S868
  • [3] Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
    Long, G. V.
    Hodi, F. S.
    Lipson, E. J.
    Schadendorf, D.
    Ascierto, P. A.
    Soto, F. A. Medina
    Maio, M.
    Hernberg, M.
    Mackiewicz, J.
    Prey, S.
    Eizmendi, M. K. Mujika
    Atkinson, V. G.
    Hassel, J. C.
    Cinat, G.
    Ratto, B.
    Rodriguez, S.
    Wang, P. T.
    Dolfi, S.
    Tawbi, H. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S664 - S665
  • [4] Nivolumab (NIVO) plus relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
    Tawbi, Hussein A.
    Hodi, F. Stephen
    Lipson, Evan J.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Matamala, Luis
    Salman, Pamela
    Gutierrez, Erika Castillo
    Rutkowski, Piotr
    Gogas, Helen
    Lao, Christopher D.
    De Menezes, Juliana Janoski
    Dalle, Stephane
    Arance, Ana Maria
    Grob, Jean-Jacques
    Keidel, Sarah
    Jonczak, Karin
    Sobiesk, Anne Marie
    Dolfi, Sonia
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
    Tawbi, Hussein A.
    Hodi, F. Stephen
    Lipson, Evan J.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Matamala, Luis
    Gutierrez, Erika Castillo
    Rutkowski, Piotr
    Gogas, Helen
    Lao, Christopher D.
    De Menezes, Juliana Janoski
    Dalle, Stephane
    Arance, Ana Maria
    Grob, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO) plus RELA or NIVO alone in RELATIVITY-047
    Lipson, E. J.
    Dolfi, S.
    Tang, H.
    Gogas, H.
    Tawbi, H. A.
    Hodi, F. S.
    Ascierto, P. A.
    Gutierrez, E. C.
    Schadendorf, D.
    Soto, F. A. Medina
    Rutkowski, P.
    Ramirez, E. Murillo
    Maio, M.
    Xu, Y.
    Desai, K.
    Yu, A.
    Demers, K.
    Miller-Moslin, K.
    Long, G. V.
    Garnett-Benson, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1290 - S1291
  • [7] Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
    Schadendorf, D.
    Tawbi, H. A.
    Hodi, F. S.
    Lipson, E. J.
    Ascierto, P. A.
    Medina Soto, F. A.
    Maio, M.
    Hernberg, M.
    Mackiewicz, J.
    Prey, S.
    Mujika Eizmendi, M. K.
    Atkinson, V. G.
    Hassel, J. C.
    Cinat, G.
    Keidel, S.
    Rodriguez, S.
    Wang, P. T.
    Dolfi, S.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2024, 35 : S723 - S724
  • [8] Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
    Lipson, Evan J.
    Tawbi, Hussein Abdul-Hassan
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Matamala, Luis
    Gutierrez, Erika Castillo
    Rutkowski, Piotr
    Gogas, Helen
    Lao, Christopher D.
    de Menezes, Juliana Janoski
    Dalle, Stephane
    Arance, Ana Maria
    Grob, Jean-Jacques
    Srivastava, Shivani
    Abaskharoun, Mena
    Simonsen, Katy L.
    Li, Bin
    Long, Georgina V.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial
    Schadendorf, Dirk
    Tawbi, Hussein
    Lipson, Evan J.
    Hodi, F. Stephen
    Rutkowski, Piotr
    Gogas, Helen
    Lao, Christopher D.
    Grob, Jean-Jacques
    Moshyk, Andriy
    Lord-Bessen, Jennifer
    Hamilton, Melissa
    Guo, Shien
    Shi, Ling
    Keidel, Sarah
    Long, Georgina, V
    EUROPEAN JOURNAL OF CANCER, 2023, 187 : 164 - 173
  • [10] Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectabl melanoma: Overall survival and response rates from REALITIVITY-047 (CA224-047)
    Long, Georgina V.
    Hodi, F. Stephen
    Lipson, Evan I.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Matamala, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
123